Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)

Kristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, Linda T. Vahdat

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalBreast cancer research and treatment
Volume146
Issue number2
DOIs
StatePublished - Jul 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this